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Abstract 
Background: Non‑synonymous mutations in dhfr and dhps genes in Plasmodium vivax are associated with sulfadox‑
ine–pyrimethamine (SP) resistance. The present study aimed to assess the prevalence of point mutations in P. vivax 
dhfr (pvdhfr) and P. vivax dhps (pvdhps) genes in three countries: Lao PDR, India and Colombia.
Methods: Samples from 203 microscopically diagnosed vivax malaria were collected from the three countries. Five 
codons at positions 13, 57, 58, 61, and 117 of pvdhfr and two codons at positions 383 and 553 of pvdhps were exam‑
ined by polymerase chain reaction‑restriction fragment length polymorphism methodology.
Results: The largest number of 58R/117 N double mutations in pvdhfr was observed in Colombia (94.3 %), while the 
corresponding wild‑type amino acids were found at high frequencies in Lao PDR during 2001–2004 (57.8 %). Size 
polymorphism analysis of the tandem repeats within pvdhfr revealed that 74.3 % of all the isolates carried the type B 
variant. Eighty‑nine per cent of all the isolates examined carried wild‑type pvdhps A383 and A553.
Conclusions: Although SP is not generally used to treat P. vivax infections, mutations in dhfr and dhps that confer 
antifolate resistance in P. vivax are common. The data strongly suggest that, when used primarily to treat falciparum 
malaria, SP can exert a substantial selective pressure on P. vivax populations, and this can lead to point mutations in 
dhfr and dhps. Accurate data on the global geographic distribution of dhfr and dhps genotypes should help to inform 
anti‑malarial drug‑use policies.
Keywords: Plasmodium vivax, Sulfadoxine–pyrimethamine, dhfr, dhps
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The antifolate drug combination sulfadoxine–pyrimeth-
amine (SP) has been used as an anti-malarial treatment 
because of its low cost and relative safety. The therapeu-
tic targets of SP in malaria parasites are dihydropteroate 
synthase (DHPS) and dihydrofolate reductase (DHFR) 
enzymes. Molecular epidemiology studies have revealed 
that the point mutations in the malaria parasite’s dhfr 
and dhps genes, which confer resistance to SP, change 
the amino acid residues around the active sites of the 
enzymes they encode [1]. Progressive accumulation of 
point mutations is associated with increasing levels of 
drug resistance in malaria parasites. In Plasmodium falci-
parum, a mutation at codon 108 of DHFR, which confers 
low-grade pyrimethamine resistance, is observed first, 
followed by additional mutations that induce high-level 
pyrimethamine resistance at codons 51 and 59 [2]. Accu-
mulation of P. falciparum DHFR (PfDHFR) mutations at 
codons 16, 51, 59, 108, and 164 is associated with pro-
gressively increasing levels of pyrimethamine resistance 
[3]. Patients infected with P. falciparum isolates carrying 
these point mutations are more likely to experience SP 
treatment failure [4, 5]. Point mutations have been iden-
tified in Plasmodium vivax DHFR (PvDHFR) at codons 
51, 58 and 117, which correspond to PfDHFR positions 
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51, 59 and 108 [6–8]. Additionally, PvDHFR mutations at 
codons 57 and 61 in combination with those at codons 
58 and 117 have been reported to correlate with SP treat-
ment failure [9, 10].
Point mutations in PfDHPS codons 436, 437, 540, 581, 
and 613 have been found to be associated with sulfadox-
ine resistance [11], and in P. vivax homologous PvDHPS 
mutations have been described at codons 382, 383, 512, 
553, and 585. Mutations in PvDHPS codon 383 and 553, 
which correspond to PfDHPS positions 437 and 581, 
have been found at high prevalence in Thailand [12, 
13]. Parasites carrying multiple mutations in pvdhfr and 
pvdhps are cleared more slowly from the patient’s blood 
during SP treatment [12]. Because monitoring of anti-
malarial drug susceptibility in P. vivax parasites in vitro 
is limited by the difficulties in culturing this parasite spe-
cies, molecular markers for SP resistance are an impor-
tant tool for evaluating SP resistance patterns in P. vivax 
populations. The well-described patterns of mutations 
related to drug resistance in P. falciparum and P. vivax 
have led to the development of the polymerase chain 
reaction-restriction fragment length polymorphism 
(PCR–RFLP) technique as a molecular surveillance tool 
for predicting SP drug resistance in specific geographical 
areas.
Molecular studies on point mutations in pvdhfr and 
pvdhps have been reported in many countries. Muta-
tions in pvdhfr that confer SP resistance are found to be 
distributed wildly in Thailand [7, 13, 14], Myanmar [15], 
Cambodia [16], Vietnam [17], Indonesia [18, 19], Papua 
New Guinea [20], the Philippines [21], Bangladesh [21], 
Nepal [21], Pakistan [22], China [23], and India [8, 24, 
25]. Although data on pvdhfr and pvdhps genotypes are 
available for many Southeast Asian countries, such data 
remain limited in some P. vivax-endemic areas, nota-
bly Lao PDR and South America. Reports from South 
America have shown that high prevalence of PvDHFR 
double mutations in codon 58 and 117 were found in 
Colombia [26, 27] while most of the samples from French 
Guiana have multiple point mutations in PvDHFR [28]. 
In this study, the prevalences of point mutations in pvd-
hfr and pvdhps were studied in three countries: Lao PDR, 
Colombia and India. India and Colombia are two coun-
tries in which P. vivax is present as the predominant 
malaria infection-causing species [29–31]. The preva-
lence of antifolate anti-malarial drug resistance in India is 
relatively high, with many recent reports of mutations in 
pvdhfr and pvdhps, whereas information on drug resist-
ance mutations in Colombia remains limited. Plasmo-
dium vivax infections are common in rural Laos [32], 
but no published information is available on pvdhfr and 
pvdhps mutations.
In this study, point mutations in pvdhfr and pvdhps 
were investigated as a tool for surveillance of SP resist-
ance. The pattern of mutations present in each study area 
provide valuable molecular information on antifolate 
drug resistance, and this information may be useful for 
epidemiological mapping of drug-resistant vivax malaria.
Methods
Parasite isolates and DNA extraction
Blood samples were collected from symptomatic P. 
vivax-infected patients as either whole blood or dried 
blood spots obtained from three different countries: Lao 
PDR, India and Colombia. Plasmodium vivax isolates 
(n  =  136) from Lao PDR were collected between 2001 
and 2004, and 45 samples were collected between 2008 
and 2012. In India, the 117 samples were collected from 
patients who attended the malaria clinic at the Calcutta 
School of Tropical Medicine, Kolkata between April 2003 
and September 2004. Fifty-three P. vivax isolates from 
Colombia were collected between 2001 and 2004 from 
five areas (Amazonas, Buenaventuno, Red Tumaco, Red 
Equapi, and Quibdó). All of the clinical isolates from the 
three countries were reported as single-species infections 
of P. vivax as determined by light microscopic examina-
tion of Giemsa-stained blood smears. This study received 
ethical approval from the Faculty of Tropical Medicine, 
Mahidol University (MUTM 2011-055-01).
Genomic DNA was extracted from all the isolates using 
a commercially available DNA extraction kit (QIAGEN, 
Germany) following the manufacturer’s instructions. 
DNA was extracted from 200  μl of whole blood or one 
dried blood spot on Whatman 3MM filter paper (1  cm 
diameter) in a final elution volume of 100 μl. DNA sam-
ples were kept at −20 °C before use.
PCR analysis of parasite species
Confirmation of the microscopic detection of P. vivax 
and detection of other cryptic species that might be in 
the samples were achieved using a nested PCR amplifica-
tion assay based on the SSU rRNA gene [33].
PCR–RFLP of PvDHFR and PvDHPS
Nested or semi-nested PCR amplification of PvDHFR 
was carried out using a method described previously 
[8]. Five point mutations (I13L, F57I/L, S58R, T61  M, 
S117  N/T) were examined by RFLP using the corre-
sponding restriction enzymes for each specific position 
in the pvdhfr gene [8]. In the case of PvDHPS, two posi-
tions (A383G and A553G) were investigated by PCR–
RFLP, following the protocol described previously [12]. 
All the DNA fragments obtained from the RFLP analy-
sis were subjected to electrophoresis on 2 % agarose gels 
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before visualization on an ultraviolet transilluminator 
after ethidium bromide staining.
Detection of size polymorphisms in PvDHFR
The tandem repeat region between nucleotides 262 and 
309 of the pvdhfr gene was PCR amplified using a proto-
col published previously [7]. Allelic size variants, which 
were assigned as described previously [7], were desig-
nated A, B and C from the largest to the smallest in base 
pairs, respectively (range, ca. 230–280 bp).
Results
Of the 203 P. vivax malaria samples from the three coun-
tries, nested PCR detected nine samples containing 
mixed infections with P. falciparum. Mixed infections 
were present at high frequency in Lao PDR (2001–2004, 
eight out of 98 samples), while in India mixed infec-
tions accounted for one of 32 samples, and there were no 
mixed infections in the 28 Colombian samples. The result 
have shown demographic history of vivax population 
and their resistant background in each region, which can 
be part of further consideration for malaria eradication 
programme.
Genotype polymorphisms within PvDHFR were exam-
ined in five codons at positions 13, 57, 58, 61, and 117 
(Fig.  1). Most of the samples collected from Lao PDR 
during 2001–2004 (89 out of 154) contained wild-type 
sequences at these five codons, compared with the 58R 
and 117  N double mutations found at high frequencies 
during 2008–2012 (29 out of 45 samples). High numbers 
of double mutations were also found within Colombia (51 
out of 53) and India (45 out of 111). The number of hap-
lotypes based on these five residues in PvDHFR was lim-
ited for Colombia, India and Lao PDR during 2008–2012 
in comparison with the samples from Lao PDR during 
2001–2004. The total numbers of PvDHFR haplotypes for 
Colombia, India and Lao PDR during 2008–2012 were 
three, five and three, respectively. The majority of the 
non-wild-type genotypes identified in all three regions 
had double mutations at codons 58R and 117 N. Double 
mutations in 58R/117 N were found at high frequency in 
the Colombian isolates (51 out of 53 samples) and in the 
Lao PDR isolates between 2008 and 2012 (29 out of 45 
samples). It was noticed that mixed genotype infections 
of wild-type and mutant parasites were found at high fre-
quency in the isolates from Lao PDR (2001–2004, 26 of 
Fig. 1 Distribution of PvDHFR and PvDHPS mutations in Colombia, India and Lao PDR. The numbers next to DHFR and DHPS represented the 
number of samples. The number count for each mutation type is shown on each graph. Amino acids in bracket after each haplotype of DHPS cor‑
responds to PvDHPS codon 383 and 553. For DHFR, there are 5 codons corresponds to PvDHFR codon 13, 57, 58, 61 and 117
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154), while there were no mixed genotype infections in 
Colombia.
Size polymorphisms in pvdhfr were investigated in 48, 
92, 45, and 117 samples from Colombia, Lao PDR (2001–
2004), Lao PDR (2008–2012) and India, respectively. 
The samples from all three countries contained a high 
prevalence of the parasite allelic variant type B, except 
Lao PDR (2008–2012), which had a high frequency of 
the allelic type C. No mixed allelic types were found in 
India and Lao PDR (2008–2012), but mixed A/B and A/C 
allelic types were found in seven and six samples, respec-
tively, from Lao PDR (2001–2004), while one and two 
samples each of mixed allelic types, A/B and A/C, respec-
tively, were identified in the Colombian samples (Fig. 2). 
Part of samples that carry allelic variant type A, B, and 
C with PCR product size approximating 280, 250, and 
230  bp, and their sequences around the central repeat 
unit were subsequently determined. Deduced amino acid 
sequences of type A, B, and C are GGDNTS GGDNTH 
GGDNTH GGDNAD, GGDNTS GGDNTH GGDNAD, 
and GGDNTS GGDNAD, respectively.
Point mutations in PvDHPS were investigated at two 
positions: A383G and A553G. The majority of the sam-
ples from all three countries contained wild-type residues 
at these two positions (Fig. 1). The 383G single mutation 
was found in all three countries at frequencies of 28.3 % 
(Colombia), 6.7  % (Lao PDR, 2001–2004), 64.4  % (Lao 
PDR, 2008–2012) and 4.5 % (India). Since the mutation 
at 383G was often found with 382S in Colombia and 
associated with SP resistance [27], eleven samples car-
rying 383G and 9 wild type samples were submitted for 
sequencing. It was found that all 20 samples carry wild 
type amino acid at codon 382. Double mutations at 383G 
and 553G and mixed genotypes of the wild-type and the 
position 383 mutation were found in one sample for each 
type within the samples from Lao PDR (2001–2004).
Haplotype classification based on five point mutations 
in PvDHFR and two point mutations in PvDHPS was 
achievable for 53, 109, 45, and 111 samples from Colom-
bia, Lao PDR (2001–2004), Lao PDR (2008–2012) and 
India, respectively. Figure  3 shows the number of hap-
lotypes identified in samples from each country for the 
15 haplotypes identified herein. Samples from Lao PDR 
(2001–2004) and India showed a high prevalence of the 
wild-type IFSTSAA haplotype at 60.6 and 49.5 %, respec-
tively. A double point mutation (58R/117 N) in PvDHFR 
in combination with wild-type PvDHPS IFRTNAA was 
found with high frequency in Colombia at 69.8 %. Com-
paring the two time periods for Lao PDR revealed that 
the period 2008–2012 contained a high frequency of 
mutant alleles. It was found that the double 58R/117  N 
mutation in PvDHFR and the single 383G mutation in 
DHPS predominated in Lao PDR between 2008 and 
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Fig. 2 Distribution of DHFR allelic size variations in Plasmodium vivax parasites from Colombia, India and Lao PDR, based on the tandem repeats 
within pvdhfr. The numbers on top of each graph represent the number of samples. Capital letters on the x‑axis represent the allelic types
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Discussion
In this study, the distribution of mutant alleles in pvdhfr 
and pvdhps was examined in three geographical regions 
with different levels of P. vivax endemicity and differing 
histories of recent drug usage. India and Colombia have a 
relatively high prevalence of P. vivax infections (60–65 %) 
compared with P. falciparum infections [30, 31, 34], while 
Lao PDR has a relatively low prevalence of P. vivax infec-
tions (20–25 %) compared with P. falciparum infections 
[32]. Perhaps because of this, the prevalence of cryptic 
P. falciparum co-infections in patients presenting with P. 
vivax infections in Lao PDR has been reported to be 10 % 
[35], a figure consistent with the data from the current 
study.
Size polymorphism regarding the GGDN repeat unit 
in PvDHFR was investigated and the result showed high 
prevalence of allelic variant type B in most of the sam-
ples. The patterns of PvDHFR point mutations in each 
allelic type were considered and the result showed no 
significant association. This result was similar to the pre-
vious findings where PvDHFR point mutations did not 
show significant association to any allelic type [6, 16, 19]. 
As shown from the crystal structure, the GGDN repeat 
region was located outside the binding pocket of PvD-
HFR enzyme and thus thought to be nonessential for 
substrate binding [36].
Surveillance of SP resistance was investigated with 
PCR-RFLP to determine specific point mutation in five 
codons of PvDHFR and two codons of PvDHPS. This 
information provides some points of view for epidemio-
logical mapping of SP resistance and their background 
situations in vivax malaria. Plasmodium vivax parasites 
from India were found to have a high frequency of dhfr 
and dhps mutations [37]. Recent studies of PvDHFR 
genotypes in India have reported high frequencies of 58R 
and 117 N double mutations [37], which is similar to the 
results for PfDHFR mutations [38, 39]. The results from 
this study showed that P. vivax parasites from India car-
ried the wild-type DHFR allele at approximately the same 
high frequency (51.4  %) as they carried the 58R/117  N 
double mutation (40.5  %), suggesting that the double 
mutation and wild-type alleles are still common in India. 
SP is not the drug of choice for treatment of P. vivax 
infections in India because P. vivax is still susceptible to 
chloroquine [30]. Therefore, the appearance of the dou-
ble mutation in PvDHFR is likely to be caused by the use 
of SP to treat P. falciparum infections, thereby exerting a 
drug selection pressure on the sympatric P. vivax popula-
tion. The data suggest that use of antifolate combinations 
for P. vivax infections should be carefully validated. The 
therapeutic efficacy of the SP drug combination should 
be investigated.
Analysis of the pvdhfr mutations in Colombia revealed 
a high frequency of the 58R and 117 N double mutation, 
similar to previous observations [27]; this double muta-
tion in DHFR was also found at high frequency in P. 
falciparum [40]. It has been proposed that use of SP in 
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Fig. 3 Distribution of DHFR‑DHPS haplotypes found in Colombia, India and Lao PDR. The numbers on top of each graph represent the number of 
samples. The x‑axis shows the various haplotypes. The amino acid sequence for each haplotype corresponds to PvDHFR codons 13, 57, 58, 61, 117, 
PvDHPS codons 383 and 553
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on both P. falciparum and P. vivax. Therefore, the SP 
combination must be carefully validated for its efficacy.
No scientific data for pvdhfr mutations in Lao PDR 
have been published. Infections caused by P. falcipa-
rum, the predominant malaria parasite species in Lao 
PDR, were found to contain double and triple mutations 
in DHFR [41–43]. This survey in Lao PDR encapsulated 
two time periods: 2001–2004 and 2008–2012. From 
2001–2004, most of the P. vivax population still carried 
the wild-type allele for dhfr. The number of mutations 
increased and double mutations were found in pvd-
hfr, while a single mutation was found in pvdhps during 
2008–2012. As P. vivax is often found to co-exist with the 
more prevalent P. falciparum in Laos, it is likely that P. 
vivax has been under heavy SP pressure before the switch 
to artemisinin-based combination therapy (ACT). It has 
been speculated that the change in treatment policy to 
ACT was timely. However, artemisinin resistance has 
already emerged and spread in Southeast Asia. Epidemi-
ological surveys aimed at identifying artemisinin-resist-
ant parasites in Lao PDR are essential for assessing the 
impact of ACT policy in this country.
Conclusion
These data suggest strongly that SP used to treat P. fal-
ciparum exerts a substantial selective pressure on the P. 
vivax population, leading to the selection of drug resist-
ance-conferring mutations in pvdhfr and pvdhps.
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